Skip to content

Ardelyx ARDX Contract With Customer, Gross To Net Sales Accruals

Contract With Customer, Gross To Net Sales Accruals at other companies

Moderna logo
ModernaMRNA
$95M-38.3%
Moderna logo
ModernaMRNA
$9M+400%
Moderna logo
ModernaMRNA
-$11M-150%
Moderna logo
ModernaMRNA
-$2M-111%
Moderna logo
ModernaMRNA
$12M-64.7%
HRO
HarrowHROW
$26.15M+32.5%

Other financials

Income statement

See full
Revenue$94.5M+27.5%
Gross profit$89.7M+45.1%
Operating income-$32.8M+9.8%
Net income-$37.6M+8.6%
EPS (diluted)-$0.15+11.8%

Balance sheet

See full
Cash & equivalents$31.2M+1.3%
Total debt$208.3M+34.3%
Total equity$148.6M+2.0%
Total assets$504.5M+23.0%

Cash flow

See full
Operating cash flow-$32.2M+16.2%
CapEx$69.0K-78.8%
Free cash flow-$32.3M+16.7%

Valuation

See full
Market cap$1.53B+25.5%
Enterprise value$1.71B+27.1%
P/S3.6×+0.2×

Profitability

See full
Gross margin92.5%+7.9pp
Operating margin-25.4%
Net margin-13.6%
FCF margin-40.9%

Returns & leverage

See full
Return on equity-39.5%
Debt / equity1.4×+0.3×
Current ratio3.5×-0.6×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept ardx:ContractWithCustomerGrossToNetSalesAccruals.

The official record: Ardelyx’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ardelyx's contract with customer, gross to net sales accruals.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ardelyx's contract with customer, gross to net sales accruals?
Ardelyx (ARDX) reported contract with customer, gross to net sales accruals of $53.43M in Q1 2026.
How has Ardelyx's contract with customer, gross to net sales accruals changed year-over-year?
Ardelyx's contract with customer, gross to net sales accruals increased by 115.6% year-over-year, from $24.79M to $53.43M.
What does contract with customer, gross to net sales accruals mean?
Represents the estimated liabilities for rebates, chargebacks, discounts, and returns associated with commercial product sales. This accrual bridges the gap between gross revenue and net revenue, reflecting the impact of pricing strategies and payer contracts. High levels of these accruals may indicate aggressive pricing or significant competitive pressure in the market.